Cardiovascular effects of current and future anti-obesity drugs.
Abstract
The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have reviewed the adverse effects on the cardiovascular system of anti-obesity drugs now retracted from the market as well as the cardiovascular profile of current drugs and potential pathways which are considered for treatment of obesity. Fenfluramine, and sibutramine were withdrawn due to increased cardiov...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U Tags: Curr Vasc Pharmacol Source Type: research
The effect of sibutramine on weight loss in obese adolescents
Conclusions : Sibutramine induced significantly more weight loss in obese adolescents compared with placebo, without significant side effects. The weight loss curve was different depending on the moment sibutramine was introduced. This finding indicates that the best time to start sibutramine is when adhesion begins to fail. Arq Bras Endocrinol Metab. 2014;58(3):243-50 (Source: Arquivos Brasileiros de Endocrinologia e Metabologia)
Source: Arquivos Brasileiros de Endocrinologia e Metabologia - May 23, 2014 Category: Endocrinology Source Type: research
Metformin associated with better cardiovascular outcomes than other glycaemic therapies
Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following inter...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Bloomgarden, Z. T. Tags: Smoking and tobacco, Epidemiologic studies, Drugs: cardiovascular system, Heart failure, Stroke, Hypertension, Diet, Obesity (nutrition), Ischaemic heart disease, Diabetes, Health education, Smoking Therapeutics Source Type: research
Illicit Distribution of Prescription Drugs: Report of Inadvertent Chloroquine Toxicity and a Market Survey of Businesses Serving Ethnic Minority Populations in Central California.
CONCLUSIONS: A variety of prescription medications, including 5 discontinued by the FDA, were available in markets serving our community's ethnic minorities. Health care workers should be aware of this public health risk, which can result in serious toxicity, as described in this case of chloroquine overdose.
PMID: 24842857 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - May 19, 2014 Category: Drugs & Pharmacology Authors: Grazier MR, Armenian P, Vohra R Tags: Ann Pharmacother Source Type: research
Monoamine reuptake site occupancy of sibutramine: relationship to antidepressant-like and thermogenic effects in rats.
Abstract
Sibutramine was formerly marketed as an anti-obesity agent. The current study investigated the relationships between monoamine reuptake site occupancy for sibutramine and both its antidepressant-like efficacy and thermogenic effects. Sibutramine's effects on locomotor activity (LMA) and food intake were also evaluated. Sibutramine occupied monoamine reuptake binding sites with the rank order of potency of NET>SERT>DAT; at 10mg/kg, po, occupancy was 95% NET, 81% SERT and 73% DAT. Sibutramine produced antidepressant-like behavior in the forced swim test; at the lowest effective dose (3mg/kg, p...
Source: European Journal of Pharmacology - May 9, 2014 Category: Drugs & Pharmacology Authors: Li YW, Langdon S, Pieschl R, Strong T, Wright RN, Rohrbach K, Lelas S, Lodge NJ Tags: Eur J Pharmacol Source Type: research
Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial
Conclusion: Bilirubin was not a risk-factor independent from other traditional cardiovascular risk-factors in our population. (Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD)
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - February 18, 2014 Category: Nutrition Authors: M.E. Jørgensen, C. Torp-Pedersen, N. Finer, I. Caterson, W.P.T. James, U.F. Legler, C. Andersson Tags: Liver abnormalities, diabetes and cardiovascular risk Source Type: research
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease
nho & I D Caterson (Source: International Journal of Obesity)
Source: International Journal of Obesity - February 11, 2014 Category: Eating Disorders and Weight Management Authors: R V SeimonD EspinozaL IversV GebskiN FinerU F LeglerA M SharmaW P T JamesW CoutinhoI D Caterson Tags: sibutramine weight loss outcome events myocardial infarction Source Type: research
Influence of eating behaviors on short-term weight loss by orlistat and anorectic agent.
This study was a sub-investigation of a 12-week randomized controlled trial for the additive effect of orlistat on sibutramine treatment. The analysis presented here was restricted to 98 women who had fulfilled the protocol. The Dutch eating behavior questionnaire and three-factor eating questionnaire were used to assess eating behaviors. Scores of emotional eating, external eating, disinhibition and hunger are significantly interrelated. Using multiple logistic analysis with adjustment for potential confounders, such as age, initial BMI and the other 2 eating behavior scores, traits of emotional eating (OR 0.30, 95% CI 0....
Source: Eating Behaviors - January 1, 2014 Category: Eating Disorders and Weight Management Authors: Kim KK, Suh HS, Hwang IC, Ko KD Tags: Eat Behav Source Type: research
New and Emerging Drug Molecules Against Obesity
Obesity has become a growing pandemic of alarming proportions in the developed and developing countries over the last few decades. The most perturbing fact regarding obesity is the increased predisposition for coronary artery disease, congestive heart failure and sudden cardiac death. The modest efficacy of current anti-obesity agents such as orlistat and the increasing withdrawals of several anti-obesity agents such as sibutramine, rimonabant have led to huge gaps in the pharmacotherapy of obesity. Lorcaserin and Phentermine-topiramate combination (phen-top) are two drugs approved by US FDA in 2012. Lorcaserin, a 5HT2C ag...
Source: Journal of Cardiovascular Pharmacology and Therapeutics - December 17, 2013 Category: Cardiology Authors: George, M., Rajaram, M., Shanmugam, E. Tags: Reviews Source Type: research
Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: A crucial role for the CYP2B6*6 allele.
CONCLUSION: The CYP2B6*6 allele influences the extent of weight reduction and pulse rate changes in patients undergoing sibutramine treatment.
PMID: 24262967 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Chemistry)
Source: International Journal of Clinical Chemistry - November 19, 2013 Category: Chemistry Authors: Hwang IC, Park JY, Ahn HY, Kim KK, Suh HS, Ko KD, Kim KA Tags: Clin Chim Acta Source Type: research
Analysis of Drugs Illegally Added into Chinese Traditional Patent Medicine Using Surface-enhanced Raman Scattering.
In this report, a surface-enhanced Raman scattering (SERS) analysis method for five kinds of illegally added drugs (rosiglitazone maleate, phenformin hydrochloride, metformin hydrochloride, pioglitazone hydrochloride and sibutramine hydrochloride) in Chinese traditional patent medicine (CTPM) has been demonstrated, including simultaneous detections of drug mixtures with CTPM. Silver colloidal, prepared by a sodium citrate reaction, was used as a SERS substrate. The optimum pH condition for each drug has also been explored because of its combined effect on protonation, surface charge, repulsion of an analyte and nanoparticl...
Source: Analytical Sciences : the international journal of the Japan Society for Analytical Chemistry - October 12, 2013 Category: Chemistry Authors: Zhang Y, Huang X, Liu W, Cheng Z, Chen C, Yin L Tags: Anal Sci Source Type: research
Association of Hypoglycemic Treatment Regimens on Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A Substudy of the SCOUT Trial.
CONCLUSIONSIn obese patients with type 2 diabetes and high risk of cardiovascular disease, monotherapy with metformin or diet-only treatment were associated with lower risk of cardiovascular events than treatment with insulin.
PMID: 24089540 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - October 2, 2013 Category: Endocrinology Authors: Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C Tags: Diabetes Care Source Type: research
The effect of antiobesity drugs on waist circumference: a mixed treatment comparison
ConclusionsOrlistat should be considered as an addition to lifestyle interventions in the treatment of obesity. Lorcaserin has recently been approved by the US Food and Drug Administration (FDA) and these results suggest that it is similar in both efficacy and safety compared to orlistat. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - September 15, 2013 Category: Endocrinology Authors: M. Chilton, A. Dunkley, P. Carter, M. J. Davies, K. Khunti, L. J. Gray Tags: ORIGINAL ARTICLE Source Type: research
The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function.
CONCLUSION: 9 months treatment with orlistat significantly improved microvascular endothelial function. This was associated with reductions in weight, BMI, BP, HR, TC and low density lipoprotein cholesterol. No effect was seen in microvascular endothelial function with sibutramine.
PMID: 24002121 [PubMed - as supplied by publisher] (Source: Clinical Hemorheology and Microcirculation)
Source: Clinical Hemorheology and Microcirculation - September 3, 2013 Category: Hematology Authors: Al-Tahami BA, Ismail AA, Bee YT, Awang SA, Salha Wan Abdul Rani WR, Sanip Z, Rasool AH Tags: Clin Hemorheol Microcirc Source Type: research
Evaluation Of The Effect Of Acute Sibutramine In Female Rats In The Elevated T‐Maze And Elevated Plus‐Maze Tests
This article is protected by copyright. All rights reserved. (Source: Basic and Clinical Pharmacology and Toxicology)
Source: Basic and Clinical Pharmacology and Toxicology - August 30, 2013 Category: Drugs & Pharmacology Authors: Raliny Oliveira Santos, Gabriela Lins Medeiros Assunção, Diogo Mizael Bessa Medeiros, Ícaro Aleksei Sousa Pinto, Keizianny Sahvedro Barros, Bruno Lobão Soares, Eunice André, Elaine Cristina Gavioli, Vanessa Soares‐Rachetti Tags: Original Article Source Type: research
